A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR Corporate Presentation March 2026 Forward Looking Statements In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number of risks, unce ...

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore ...

Core Insights - electroCore, Inc. reported net sales of $8.7 million for Q3 2025, a 33% increase compared to Q3 2024, and year-to-date net sales of $22.8 million, reflecting a 26% increase compared to the first nine months of 2024 [1][3][8] - The company has increased its revenue guidance for the full year 2025 to a range of $31.5 million to $32.5 million, driven by strong sales growth in the VA market for its prescription products [2][14] Financial Performance - For Q3 2025, net sales were $8.7 million, up from $6.6 million in Q3 2024, with a gross profit of $7.5 million, representing an 86% gross margin compared to 84% in the previous year [3][4][10] - Prescription device sales increased by 19% year-over-year, while health and wellness products saw a significant growth of 121% in the same period [4][8] - Total operating expenses for Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024, with selling, general, and administrative expenses rising to $9.7 million [6][7] Cash Position - As of September 30, 2025, total cash, including cash equivalents and marketable securities, was $13.2 million, an increase from $12.2 million at the end of 2024 [1][13][22] Loss and Adjusted EBITDA - The net loss for Q3 2025 was $3.4 million, or $0.40 per share, compared to a net loss of $2.5 million, or $0.31 per share, in Q3 2024 [10][20] - Adjusted EBITDA net loss for Q3 2025 was $2.0 million, slightly improved from a loss of $2.1 million in Q3 2024 [11][26] Future Outlook - The company anticipates reaching $12.0 million in quarterly revenue and achieving its first quarter of positive adjusted EBITDA in the second half of 2026 [14]

Company Leadership Changes - Peter Cuneo has departed from the Board of Directors of electroCore, Inc., with Thomas J. Errico, MD, elected as the new Chairman of the Board effective September 2, 2025 [1][2] - Cuneo will continue to serve as a strategic advisor to the company [1] - CEO Dan Goldberger expressed gratitude for Cuneo's contributions since 2020, highlighting his role in the company's turnaround [2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [3] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. has appointed Kelly Benning as the Senior Vice President of Truvaga, effective July 21, 2025, bringing nearly 30 years of experience in digital health and consumer wellness [1][3] - Ms. Benning emphasizes the shift in the wellness market towards personalized, consumer-centric solutions, aiming to innovate and refine technology to empower individuals in managing their well-being [2][3] - The company focuses on building a movement around science-backed wellness solutions and plans to leverage strategic partnerships for greater accessibility to its consumer devices [2][3] Company Overview - electroCore is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through non-invasive bioelectronic technologies [5] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both targeting chronic pain syndromes [5] - electroCore also markets Truvaga™, a handheld device aimed at promoting general wellness and human performance [5] Leadership Background - Kelly Benning has a proven track record in bringing digital health products to market, including the first FDA-cleared watch for blood pressure monitoring [2][3] - Her previous roles include executive positions at LiveMetric, IBM Watson Health, and other healthcare enterprises, showcasing her extensive experience in the industry [3] - The CEO of electroCore, Dan Goldberger, expressed confidence in Ms. Benning's ability to expand the company's direct-to-consumer strategy [4]

Core Insights - ReShape Lifesciences has received a Notice of Allowance for a patent on its Diabetes Neuromodulation system, which utilizes vagus nerve modulation to treat Type 2 diabetes and hypoglycemia, with patent protection extending until August 4, 2037 [1][2] - The technology is designed to regulate blood glucose levels through targeted vagal nerve modulation, using a unique energy-efficient algorithm that consumes approximately 10 times less energy than traditional methods, allowing for smaller devices and longer battery life [2][3] - The company has completed preclinical development, demonstrating the system's efficacy in boosting insulin production and managing blood glucose levels, while remaining compatible with standard implantable pulse generators [2][3] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band systems and non-surgical options like the Obalon balloon technology [4] - The company is in the process of selling its assets, including the Lap-Band System and the Diabetes Neuromodulation system, to Biorad Medisys, which will take ownership of the DBSN™ system upon closing the transaction [5] Technology Details - The ReShape Diabetes Neuromodulation system is a minimally invasive implant that delivers bio-electronic neuromodulation to regulate plasma glucose by stimulating the pancreas and blocking signals to the liver [3] - The system is designed to be reversible and adjustable, potentially representing a significant advancement in personalized medicine compared to existing vagus nerve stimulation methods [3] Intellectual Property - The company holds a robust intellectual property portfolio with 63 issued or pending patents covering various aspects of its technology, including vagal neuromodulation and glucose regulation, which supports its commercialization efforts [2]